WO1998005797B1 - Criblage de medicaments du cancer de la prostate - Google Patents
Criblage de medicaments du cancer de la prostateInfo
- Publication number
- WO1998005797B1 WO1998005797B1 PCT/US1997/013888 US9713888W WO9805797B1 WO 1998005797 B1 WO1998005797 B1 WO 1998005797B1 US 9713888 W US9713888 W US 9713888W WO 9805797 B1 WO9805797 B1 WO 9805797B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enhancer
- cells
- gene
- expression
- psa
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract 3
- 239000003560 cancer drug Substances 0.000 title 1
- 238000007877 drug screening Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 230000000694 effects Effects 0.000 claims abstract 5
- 239000003623 enhancer Substances 0.000 claims 17
- 230000002708 enhancing Effects 0.000 claims 17
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 12
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 12
- 210000004027 cells Anatomy 0.000 claims 10
- 102000004190 Enzymes Human genes 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 6
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 210000002307 Prostate Anatomy 0.000 claims 3
- 230000001809 detectable Effects 0.000 claims 3
- 239000006166 lysate Substances 0.000 claims 3
- 238000011144 upstream manufacturing Methods 0.000 claims 3
- 239000005089 Luciferase Substances 0.000 claims 2
- 108060001084 Luciferase family Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 230000002934 lysing Effects 0.000 claims 2
- 102000020495 EC 3.4.21.35 Human genes 0.000 claims 1
- 108030007092 EC 3.4.21.35 Proteins 0.000 claims 1
- WYZDXEKUWRCKOB-YDSAWKJFSA-N Mestanolone Chemical compound C([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 WYZDXEKUWRCKOB-YDSAWKJFSA-N 0.000 claims 1
- CCCIJQPRIXGQOE-XWSJACJDSA-N Metribolone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 claims 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 claims 1
- 238000004020 luminiscence type Methods 0.000 claims 1
- 210000004962 mammalian cells Anatomy 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920000023 polynucleotide Polymers 0.000 claims 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Abstract
On décrit le criblage de composés en vue de rechercher chez ceux-ci une activité d'inhibition de la prolifération des cellules du cancer de la prostate. On emploie une lignée cellulaire que l'on peut utiliser dans un matériel classique de détermination de l'activité de composés, dans lequel cette lignée cellulaire utilise un marqueur dont l'expression est sensible à des composés actifs sur le plan thérapeutique.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97937149A EP0918884A1 (fr) | 1996-08-06 | 1997-08-06 | Criblage de medicaments du cancer de la prostate |
| AU39729/97A AU3972997A (en) | 1996-08-06 | 1997-08-06 | Prostate cancer drug screening |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/692,759 | 1996-08-06 | ||
| US08/692,759 US5783435A (en) | 1996-08-06 | 1996-08-06 | Prostate cancer drug screenings |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998005797A1 WO1998005797A1 (fr) | 1998-02-12 |
| WO1998005797B1 true WO1998005797B1 (fr) | 1998-05-14 |
| WO1998005797A9 WO1998005797A9 (fr) | 1998-07-09 |
Family
ID=24781904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/013888 WO1998005797A1 (fr) | 1996-08-06 | 1997-08-06 | Criblage de medicaments du cancer de la prostate |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US5783435A (fr) |
| AU (1) | AU3972997A (fr) |
| WO (1) | WO1998005797A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE376062T1 (de) | 1997-08-04 | 2007-11-15 | Cell Genesys Inc | Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung |
| AU3292499A (en) * | 1998-02-12 | 1999-08-30 | Calydon, Inc. | Prostate cancer drug screening |
| WO2000012763A1 (fr) * | 1998-09-02 | 2000-03-09 | University Of Rochester | Sequences d'acide nucleique regulatrices specifiques de la prostate |
| WO2000015834A2 (fr) * | 1998-09-15 | 2000-03-23 | Signalgene Inc. | Marqueur au niveau du gene recepteur des hormones androgenes pour la determination de la sensibilite au cancer du sein |
| WO2000018961A2 (fr) * | 1998-09-30 | 2000-04-06 | Millennium Pharmaceuticals, Inc. | Analyse de l'expression d'acides nucleiques et de polypeptides specifiques utiles pour le diagnostic et le traitement du cancer de la prostate |
| US6872811B1 (en) | 1998-09-30 | 2005-03-29 | Millennium Pharmaceuticals, Inc. | HRPCa9 and HRPCa10 nucleic acids and polypeptides |
| US6495130B1 (en) | 1998-12-30 | 2002-12-17 | Calydon, Inc. | Target cell-specific adenoviral vectors containing E3 and methods of use thereof |
| JP2002541779A (ja) * | 1999-02-24 | 2002-12-10 | ザ ジュネラル ホスピタル コーポレーション | シグナル伝達中間体のクローニング方法 |
| DE60137137D1 (de) * | 2000-09-26 | 2009-02-05 | Univ Emory | Viren gegen hypoxische zellen und gewebe |
| US7285414B2 (en) | 2000-09-26 | 2007-10-23 | Emory University | Viruses targeted to hypoxic cells and tissues |
| DE10061161A1 (de) * | 2000-11-30 | 2002-06-20 | Schering Ag | Neue humane Androgenrezeptor-Varianten |
| JP2003018987A (ja) * | 2001-06-25 | 2003-01-21 | Okazaki National Research Institutes | 遺伝子導入細胞及びそれを用いた撹乱物質の検出法 |
| TW200418988A (en) * | 2002-09-30 | 2004-10-01 | Oncotherapy Science Inc | Method for diagnosing prostate cancer |
| EP1727831A1 (fr) * | 2004-03-23 | 2006-12-06 | Oncotherapy Science, Inc. | Genes et polypeptides associes aux cancers de la prostate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100355647B1 (ko) * | 1993-09-01 | 2002-12-28 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 항에스트로젠화합물의스크리닝방법 |
| US5830686A (en) * | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5919652A (en) * | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
-
1996
- 1996-08-06 US US08/692,759 patent/US5783435A/en not_active Expired - Fee Related
-
1997
- 1997-08-06 WO PCT/US1997/013888 patent/WO1998005797A1/fr not_active Application Discontinuation
- 1997-08-06 AU AU39729/97A patent/AU3972997A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998005797B1 (fr) | Criblage de medicaments du cancer de la prostate | |
| Carbone et al. | Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemia-associated PML-retinoic acid receptor fusion protein | |
| Reisman et al. | Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression | |
| Fiorentino et al. | CTCF and BORIS regulate Rb2/p130 gene transcription: a novel mechanism and a new paradigm for understanding the biology of lung cancer | |
| Eguchi et al. | Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins | |
| Brady et al. | Regulation of p53 and MDM2 activity by MTBP | |
| MX9606476A (es) | Inhibicion citoplasmica de expresion de genes. | |
| Chen et al. | Downregulation of connexin 26 in human lung cancer is related to promoter methylation | |
| Verkaik et al. | Silencing of CD44 expression in prostate cancer by hypermethylation of the CD44 promoter region | |
| Hsu et al. | Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner | |
| Vadlamudi et al. | Genomic structure and promoter analysis of the p62 gene encoding a non-proteasomal multiubiquitin chain binding protein | |
| Sen et al. | Genome-wide positioning of bivalent mononucleosomes | |
| Silverman et al. | Role of sequences within the first intron in the regulation of expression of eukaryotic initiation factor 2 alpha. | |
| Butcher et al. | Genomic organization of human arylamine N-acetyltransferase Type I reveals alternative promoters that generate different 5′-UTR splice variants with altered translational activities | |
| Brzóska et al. | Basal PIR expression in HeLa cells is driven by NRF2 via evolutionary conserved antioxidant response element | |
| Zhan et al. | A novel long noncoding RNA, lncR-125b, promotes the differentiation of goat skeletal muscle satellite cells by sponging miR-125b | |
| Dong et al. | 17β‐Hydroxysteroid Dehydrogenases in Human Bone Cells | |
| Ziober et al. | Identification and characterization of the cell type-specific and developmentally regulated α7 integrin gene promoter | |
| AUPO128096A0 (en) | Biosensors | |
| Fu et al. | Epigenetic regulation of proprotein convertase PACE4 gene expression in human ovarian cancer cells | |
| Valdez et al. | Repression of androgen receptor transcription through the E2F1/DNMT1 axis | |
| Walter et al. | Characterization of laminin-332 gene expression in molecular subtypes of human bladder cancer | |
| Ishikawa et al. | Testosterone inhibits matrix metalloproteinase-1 production in human endometrial stromal cells in vitro | |
| US5643720A (en) | Method of inhibiting transcription utilizing nuclear receptors | |
| Stearns et al. | Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines |